| Literature DB >> 34488536 |
Bo Wang1, Song Gong2, Wenkai Shao2, Lizhi Han2, Zilin Li2, Zhichao Zhang1, Yang Zheng1, Fang Ouyang1, Yan Ma1, Weihua Xu2, Yong Feng2.
Abstract
Steroid-induced osteonecrosis of the femoral head (SONFH) is a progressive disease that leads to an increased disability rate. This study aimed to ascertain biomarkers, infiltrating immune cells, and therapeutic drugs for SONFH. The gene expression profile of the GSE123568 dataset was downloaded from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) were identified using the NetworkAnalyst platform. Functional enrichment, protein-protein interaction network (PPI), and module analyses were performed using Metascape tools. An immune cell abundance identifier was used to explore immune cell infiltration. Furthermore, hub genes were identified based on maximal clique centrality (MCC) evaluation using cytoHubba application and confirmed by qRT-PCR using clinical samples. Finally, the L1000 platform was used to determine potential drugs for SONFH treatment. The SONFH mouse model was used to determine the therapeutic effects of aspirin. In total, 429 DEGs were identified in SONFH samples. Functional enrichment analysis showed that these DEGs were enriched in myeloid leukocyte activation and osteoclast differentiation processes. A set of nine immune cell types was confirmed to be markedly different between the SONFH and control samples. All 10 hub genes were significantly highly expressed in the serum of SONFH patients, as shown by qRT-PCR. Finally, the therapeutic effect of aspirin on SONFH was examined in animal experiments. Taken together, our data revealed the hub genes and infiltrating immune cells in SONFH, and we also screened potential drugs for use in SONFH treatment.Entities:
Keywords: SONFH; biomarker; immune cell infiltration; therapeutics
Mesh:
Substances:
Year: 2021 PMID: 34488536 PMCID: PMC8815624 DOI: 10.1080/21655979.2021.1972081
Source DB: PubMed Journal: Bioengineered ISSN: 2165-5979 Impact factor: 3.269
Figure 1.Identification of DEGs in SONFH. (a) Hierarchical clustering heat map of SONFH samples and control samples based on identified DEGs (50 genes shown). (b) Volcano plot of the DEGs between SONFH samples and control samples
Figure 2.Function enrichment analysis and PPI network construction. (a) GO functional enrichment analysis of BP. (b) GO functional enrichment analysis of CC. (c) GO functional enrichment analysis of MF. (d) KEGG pathway analyses results of the DEGs. (e) The PPI network of the DEGs. (f) The six most significant modules were obtained from the PPI network
The six most significant MCODE components were extracted from the PPI
| MCODE_ALL | R-HSA-373076 Class A/1 (Rhodopsin-like receptors); |
|---|---|
| MCODE_1 | GO:0042026 protein refolding; |
| MCODE_2 | R-HSA-373076 Class A/1 (Rhodopsin-like receptors); |
| MCODE_3 | GO:0002755 MyD88-dependent toll-like receptor signaling pathway; |
| MCODE_4 | R-HSA-416476 G alpha (q) signaling events; |
| MCODE_5 | GO:0008285 negative regulation of cell proliferation |
| MCODE_6 | GO:0045669 positive regulation of osteoblast differentiation; GO:0045778 positive regulation of ossification; |
Figure 3.The differences in immune cell infiltration between SONFH and normal controls. (a) The relative percentage of 24 subpopulations of immune cells in 40 samples from the GSE123568 dataset. (b) Correlation analyses of the 24 subpopulations of immune cells estimated in 40 samples from GSE123568. (c) Heat map of the 24 subpopulations of immune cells estimated in 40 samples from GSE123568. (d) The differences in immune cell infiltration between SONFH patients and normal controls (*p values < 0.05 were considered statistically significant)
Figure 4.The 10 most highly expressed hub genes in the PPI network as confirmed with RT-PCR. (a) The 10 most highly expressed hub genes in the PPI network as determined by cytoHubba. (b) RT-PCR validation of the hub genes in SONFH and normal controls. All experiments were performed in triplicate, and the results are presented as the means ± SD. (*p < 0.05)
The top 10 compounds with activity against SONFH as predicted via connectivity map
| Score | Name | Description | Target |
|---|---|---|---|
| −99.68 | Phylloquinone | Vitamin K | BGLAP, GGCX |
| −99.58 | cholic-acid | Bile acid | ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B |
| −99.58 | MRS-1220 | Adenosine receptor antagonist | ADORA2B, ADORA3 |
| −99.54 | Bucladesine | Adenosine receptor agonist | PRKACA |
| −99.51 | Isotretinoin | Retinoid receptor agonist | CYP2B6, CYP2C19, CYP2C8, CYP3A5, CYP3A7, NR2C2, PPARD, RARA, RARB, RARG, RORB |
| −99.22 | Doxercalciferol | Vitamin D receptor agonist | VDR |
| −98.8 | Betahistine | Histamine receptor agonist | HRH1, HRH3 |
| −98.8 | Aspirin | Cyclooxygenase inhibitor | AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53 |
| −98.73 | Maraviroc | CC chemokine receptor antagonist | CCR5, CYP3A5 |
| −98.38 | SR-27897 | CCK receptor antagonist | CCKAR |
Figure 5.Identification of the therapeutic effect of aspirin in GC-induced ONFH. (a) Schematic diagram of the treatment of different groups of mice. H&E staining of representative femoral heads in each group. (b) Bone volume/total volume ration (BV/TV) in each group. (c) Empty lacunae rate in each group. (d-f) H&E staining of representative femoral heads in each group (scale bar = 100 μm). (g-i) TRAP staining of representative femoral heads in each group (scale bar = 100 μm). (j-l) Relative Runx2, RANKL and PTGS2 mRNA expression in femoral heads in each group. All experiments were performed in triplicate, and the results are presented as the means ± SD. (*p < 0.05 versus the control; #p < 0.05 versus the GC)